Alvelestat is under clinical development by Mereo Biopharma Group and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Alvelestat’s likelihood of approval (LoA) and phase transition for Alpha-1 Antitrypsin Deficiency (A1AD) took place on 19 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Alvelestat Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Alvelestat overview

Alvelestat is under development for the treatment of graft-versus-host disease, alpha-1 antitrypsin deficiency lung disease and bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation, and covid-19 associated acute lung injury. It is a small molecule administered orally in the form of tablet. It acts as a neutrophil elastase inhibitor. It was also under development for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis and bronchiectasis and type 2 diabetes.

Mereo Biopharma Group overview

Mereo Biopharma Group is a specialty bio-pharmaceutical company. The company develops novel medicines for the treatment of rare and specialty diseases. It’s pipeline products include BPS-804, which is used for the treatment of brittle bone syndrome and BCT-197, and Etigilimab (MPH-313), which treats solid tumors. Mereo Biopharma Group also offers BGS-649, an orally active aromatase inhibitor developed for the treatment of obese men with hypogonadotropic hypogonadism and its Navicixizumab (OMP-305B83) is in Phase 1 clinical trial which treats platinum-resistant ovarian cancer. The company collaborates with biotechnology and pharmaceutical companies. Mereo Biopharma Group is headquartered in London, England, the UK.

Quick View Alvelestat LOA Data

Report Segments
  • Innovator
Drug Name
  • Alvelestat
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.